New hope for stomach cancer patients Who've tried everything?
NCT ID NCT07096609
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug lenvatinib in 48 adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to three standard treatments. Participants take lenvatinib capsules daily, and researchers will measure how many patients have their disease controlled (shrink or stay stable) after 12 weeks. The goal is to see if lenvatinib can provide a new option when other drugs no longer work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lenvatinib (a targeted cancer drug taken as a daily capsule)
What this could lead to
If successful, lenvatinib could offer a new treatment option for people with advanced GIST who have run out of standard therapies.
What could go wrong
This is an early phase 2 study with only 48 participants, so results may not apply broadly. Lenvatinib can cause side effects like high blood pressure, fatigue, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••